Aide Biotechnology: Announcement on the progress of repurchasing the company's shares
Securities code: 300685 Securities abbreviation: Aide Biotechnology Announcement number: 2026-005
Xiamen Aide Biomedical Technology Co., Ltd.
Announcement on the progress of repurchasing the company's shares
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Xiamen Aide Biomedical Technology Co., Ltd. (hereinafter referred to as the "Company" or "Aide Bio") held the first extraordinary shareholders' meeting of 2025 on November 10, 2025, and reviewed and approved the "Proposal on the Repurchase of the Company's Shares through Centralized Bidding Transactions". The company uses its own funds and/or self-raised funds to repurchase shares through centralized bidding to cancel and reduce the company's registered capital; the total repurchase funds shall be no less than RMB 100 million and no more than RMB 200 million. The specific repurchase fund amount shall be based on the actual repurchase amount when the repurchase is completed; the implementation period of the repurchase of shares is within 12 months from the date of the company's shareholders meeting to review and approve the repurchase plan. For details, please refer to the company's "Repurchase Report" published on cninfo.com on November 18, 2025.
In accordance with the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 9 - Repurchase of Shares" and other relevant regulations, the relevant progress of the company's share repurchase is hereby announced as follows:
1. Repurchase progress as of the end of last month
As of February 28, 2026, the company had repurchased 937,100 shares through a dedicated securities account and centralized bidding transactions, accounting for 0.24% of the company's current total share capital. The highest transaction price of the repurchased shares was 22.16 yuan/share, and the lowest transaction price was 20.50 yuan/share. The total amount paid was 19,996,346.70 yuan (excluding transaction fees). This repurchase complies with the company's established share repurchase plan and the requirements of relevant laws and regulations.
2. Other instructions
The company's time for repurchasing shares, the number of shares repurchased, and the entrustment time period for centralized bidding transactions are all in compliance with the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 9 - Repurchase of Shares" and other relevant regulations.
- The company did not repurchase shares during the following periods:
(1) From the date when a major event that may have a significant impact on the trading price of the company's securities and its derivatives occurs or during the decision-making process to the date of disclosure in accordance with the law;
(2) Other circumstances specified by the China Securities Regulatory Commission and Shenzhen Stock Exchange.
- Companies that repurchase shares through centralized bidding transactions meet the following requirements:
(1) The entrusted price shall not be the price that limits the trading increase of the company’s stock on that day;
(2) No share repurchase entrustment shall be made during the opening call auction, closing call auction and trading days when the stock price has no limit on the price increase or decrease of the Shenzhen Stock Exchange;
(3) Other requirements stipulated by the China Securities Regulatory Commission and Shenzhen Stock Exchange.
- The company will continue to implement this repurchase plan within the repurchase period based on market conditions, and will perform information disclosure obligations in a timely manner in accordance with relevant laws, regulations and normative documents. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Xiamen Aide Biomedical Technology Co., Ltd.
March 2, 2026